Neutralization and adoptive transfer studies revealed that superior antitumor activity by combination therapy was dependent on the presence of the T cells, and CD73 expression on T cells directly impaired the 4-1BB-elicited anti-tumor effect. The gene discussed is NT5E; the disease is neoplasm.